Trithiocarbonates: exploration of a new head group for HDAC inhibitors

  • Bioorg Med Chem Lett. 2007 Sep 1;17(17):4746-52. doi: 10.1016/j.bmcl.2007.06.063.
Florian Dehmel  1 Thomas Ciossek Thomas Maier Steffen Weinbrenner Beate Schmidt Martin Zoche Thomas Beckers
Affiliations
  • 1. Altana Pharma AG, a Member of the Nycomed Group, Byk-Gulden-Strasse 2, D-78467, Germany. [email protected]
Abstract

Inhibition of histone deacetylases class I/II Enzymes is a new, promising approach for Cancer therapy. In the present study, we disclose a new structural class of HDAC inhibitors with the trithiocarbonate motif. A clear structure-activity-relationship was obtained for the cap-linker motif and the putative Zn(2+) complexing head group. Selected analogs display potent inhibition of HDAC enzymatic activity and a cellular potency comparable to that of suberoylanilide hydroxamic acid (SAHA), recently approved for treatment of patients with advanced cutaneous T-cell lymphoma.

Products